Trial · NCT03452527
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
NCT03452527, Phase 2, Terminated, Iconic Therapeutics, Inc.; results first posted 2021-03-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD). Trials, record NCT03452527. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03452527
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- NCT number
- NCT03452527
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Iconic Therapeutics, Inc.
- Conditions
- Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- ICON-1, aflibercept
- First posted
- 2018-03-02
- Last updated
- 2021-04-13
- Results first posted
- 2021-03-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Choroidal Neovascularization (CNV) Over Time | Month 9 | Mean change from baseline in CNV area in the study eye |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) Over Time | Month 9 | Mean change from baseline in BCVA letter score in the study eye |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Choroidal Neovascularization (CNV) Over Time | Month 9 | The change in choroidal neovascularization by OCT-A, reported as assessed by the investigators. The changes did not correlate with the change in choroidal neovascularization by FA and therefore further analysis was not performed. | participants | NUMBER |
| SECONDARY | Change in Best Corrected Visual Acuity (BCVA) Over Time | Month 9 | Due to the small sample size and early termination of the study conclusions can not be accurately made from the available data. | Letters | MEAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Maintenance Therapy | CNV Size-Smaller | 2 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Combination Therapy | CNV Size-Smaller | 5 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Maintenance Therapy | CNV Size-No Change | 2 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Combination Therapy | CNV Size-No Change | 2 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Maintenance Therapy | CNV Size- Larger | 0 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Combination Therapy | CNV Size- Larger | 1 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Maintenance Therapy | CNV Size-Cannot Grade | 1 | participants | |
| Change in Choroidal Neovascularization (CNV) Over Time | ICON-1 Combination Therapy | CNV Size-Cannot Grade | 0 | participants | |
| Change in Best Corrected Visual Acuity (BCVA) Over Time | ICON-1 Maintenance Therapy | 1 | Full Range -2 to 7 | Letters | |
| Change in Best Corrected Visual Acuity (BCVA) Over Time | ICON-1 Combination Therapy | 0 | Full Range -3 to 5 | Letters |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ICON-1 Maintenance Therapy | 7 | |
| Overall Study | STARTED | ICON-1 Combination Therapy | 8 | |
| Overall Study | COMPLETED | ICON-1 Maintenance Therapy | 4 | |
| Overall Study | COMPLETED | ICON-1 Combination Therapy | 4 | |
| Overall Study | NOT COMPLETED | ICON-1 Maintenance Therapy | 3 | |
| Overall Study | NOT COMPLETED | ICON-1 Combination Therapy | 4 |
Source ClinicalTrials.gov
Adverse events76
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Macular Fibrosis | Eye disorders | ICON-1 Maintenance Therapy | 1 | 7 | 1 |
| other | Macular Fibrosis | Eye disorders | ICON-1 Combination Therapy | 1 | 8 | 1 |
| other | Photopsia | Eye disorders | ICON-1 Maintenance Therapy | 1 | 7 | 1 |
| other | Photopsia | Eye disorders | ICON-1 Combination Therapy | 1 | 8 | 1 |
| other | Retinal Haemorrhage | Eye disorders | ICON-1 Maintenance Therapy | 1 | 7 | 1 |
| other | Retinal Haemorrhage | Eye disorders | ICON-1 Combination Therapy | 1 | 8 | 1 |
| other | Subretinal Fluid | Eye disorders | ICON-1 Maintenance Therapy | 0 | 7 | 0 |
| other | Subretinal Fluid | Eye disorders | ICON-1 Combination Therapy | 2 | 8 | 2 |
| other | Choroidal Neovascularization | Eye disorders | ICON-1 Maintenance Therapy | 0 | 7 | 0 |
| other | Choroidal Neovascularization | Eye disorders | ICON-1 Combination Therapy | 1 | 8 | 1 |
1 to 10 of 76Source ClinicalTrials.gov
See all 76 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ICON-1 Maintenance Therapy | 0 | 7 |
| Total, all-cause mortality | ICON-1 Combination Therapy | 0 | 8 |
| Total, other adverse events | ICON-1 Maintenance Therapy | 6 | 7 |
| Total, other adverse events | ICON-1 Combination Therapy | 8 | 8 |
| Total, serious adverse events | ICON-1 Maintenance Therapy | 2 | 7 |
| Total, serious adverse events | ICON-1 Combination Therapy | 1 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| ICON-1 Maintenance Therapy vs ICON-1 Combination Therapy: deaths from any cause | Trial comparisons |
| ICON-1 Maintenance Therapy vs ICON-1 Combination Therapy: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03452527
GET https://conductscience.org/api/trials/v1/NCT03452527/events?page=2